ImmunoCellular Therapeutics (OTC:IMUC) said Monday it has appointed Helen Kim to the board of directors, and as the chairperson of the company’s product strategic committee.
Kim holds a Bachelor of Science in Chemical Engineering from Northwestern University and a Masters of Business Administration from the University of Chicago.
Her previous work experience includes: Kosan Biosciences Inc., where she restructured and repositioned the company prior to its sale to Bristol-Myers Squibb (NYSE:BMY). She has also held positions at Affymax (NASDAQ:AFFY), Onyx Pharmaceuticals (NASDAQ:ONXX), Protein Design Labs (NASDAQ:PDLI) and Chiron Corp.
Currently, Kim serves on the board at Sunesis Pharmaceuticals (NASDAQ: SNSS) and as Chief Business Officer for NGM Biopharmaceuticals, a privately held drug company.
ImmunoCellular Therapeutics develops immune-based therapies for the treatment of brain and other cancers. The company has started a phase two trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor antigens for glioblastoma, a malignant brain tumor.
The Los Angeles, California-based company’s shares fell 4.76% to $1.60 Monday on the OTC market at 3.31pm EDT.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment